Concepedia

Author

Edward Arrowsmith

Tennessee Oncology

Also Known As

E ARROWSMITH, E Arrowsmith, E. Arrowsmith, E. R. Arrowsmith, Edward Arrowsmith, Edward R. Arrowsmith, Mehmet Bilen

84

Publications

1.9K

Citations

22

H-Index

37

Concepts

All Affiliations

Tennessee OncologySarah CannonFlorida Cancer Specialists & Research InstituteUniversity of WashingtonOncology Hematology Care
EA

About

Edward Arrowsmith is an author at Tennessee Oncology specializing in radiation oncology, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

16

684

2

Health Sciences

5

5

157

3

Immunology

3

3

50

4

Gastroenterology

2

2

224

5

Obstetrics

1

1

33

Edward Arrowsmith

×

32

Publications

1.5K

Citations

20

H-Index

YearCitations

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh,

Annals of Oncology

2016

143

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Scott S. Tykodi, Lucio Gordan, Robert Alter,

Journal for ImmunoTherapy of Cancer

2022

126

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane,

Clinical Genitourinary Cancer

2020

101

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

Toni K. Choueiri, David F. McDermott, Jaime R. Merchan,

The Lancet Oncology

2023

96

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer

Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse,

Cancer Medicine

2013

90

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

J. G. Berdeja, Lowell L. Hart, Joseph R. Mace,

Haematologica

2015

87

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma

John D. Hainsworth, Jeffrey R. Infante, David R. Spigel,

Cancer Investigation

2011

87

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh,

Journal of Clinical Oncology

2014

81

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

Kimmie Ng, Josep Tabernero, Jimmy J. Hwang,

Clinical Cancer Research

2013

67

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

John D. Hainsworth, James A. Reeves, Joseph R. Mace,

Targeted Oncology

2016

59

Page 1